Caxton Associates LP Intellia Therapeutics, Inc. Transaction History

Caxton Associates LP

  • $2.65 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022
SELL
$58.27 - $118.99 $184,832 - $377,436
-3,172 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$100.76 - $138.36 $319,610 - $438,877
3,172 New
3,172 $375,000
Q2 2021

Aug 16, 2021
SELL
$60.88 - $161.91 $239,867 - $637,925
-3,940 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$46.59 - $83.68 $183,564 - $329,699
3,940 New
3,940 $316,000

Others Institutions Holding NTLA

# of Institutions
314
Shares Held
91.5M
Call Options Held
442K
Put Options Held
880K
View Full List

About Intellia Therapeutics, Inc.

NTLA Quotes by TradingView
  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $926M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Caxton Associates LP Portfolio

Follow Caxton Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Caxton Associates LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email